Prediabetes and progression to type 2 diabetes — compounds assessed
The 3 compounds the Institute assesses in prediabetes and progression to type 2 diabetes.
§4Compounds assessed
Compounds the Institute assesses in this indication, with the class of each and its overall certainty. A compound appears here whether or not the evidence supports its use, because recording that a compound has been studied and found wanting is as much part of the assessment as recording that one has not.
-
Time to onset of type 2 diabetes over 160 weeks: hazard ratio 0.21 — Downgraded for the confounding effect of treatment on the diagnostic measure itself.
Moderate -
Progression to type 2 diabetes at 176 weeks reduced by 94 % in the prediabetes cohort — Prespecified extension of one trial; the very large effect partly reflects glycaemic masking during treatment, which the Institute notes explicitly.
Moderate -
Reversion to normoglycaemia in 84.1 % of participants with prediabetes at baseline versus 47.8 % with placebo (STEP 1) — Exploratory subgroup analysis; no incident-diabetes outcome trial has reported.
Low
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, Lau DCW, le Roux CW, Violante Ortiz R, Jensen CB, Wilding JPH. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine 2015;373(1):11–22. doi:10.1056/NEJMoa1411892 · PMID 26132939
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.